In a Phase I clinical trial (NCT04640545), researchers evaluated the efficacy of LBL-007 in combination with Toripalimab for patients with advanced or metastatic melanoma, irrespective of their prior exposure to anti-PD-1 therapies. The gene discussed is PDCD1; the disease is metastatic melanoma.